


## Supplemental Figure and Tables

**Supplemental Figure 1:** Diagram of patient inclusion and exclusion for propensity score matching analysis



\*692 Unvaccinated, 142 partially vaccinated

**Supplemental Table 1:** Sensitivity analysis for baseline characteristics and outcomes before and after propensity score matching (excluding partially vaccinated SOTR)

	Before Propensity Score Match (N=2631)			After Propensity Score Match (N=1668)		
	Fully Vaccinated (n=1427)	Unvaccinated (n=926)	P-Value	Fully Vaccinated (n=829)	Unvaccinated (n=829)	P-Value
<b>Age – Mean (SD)</b>	58.52 (13.64)	53.60 (15.76)	<0.001	54.95 (14.50)	54.90 (15.12)	0.94
<b>Sex</b>						
Female	561 (39.31%)	341 (36.83%)	0.23	322 (38.84%)	315 (38.00%)	0.72
Male	866 (60.69%)	585 (63.17%)		507 (61.16%)	514 (62.00%)	
<b>Race</b>						
White	949 (66.50%)	524 (56.59%)	<0.001	484 (58.38%)	496 (59.83%)	0.94
Black	281 (19.69%)	259 (27.97%)		221 (26.66%)	212 (25.57%)	
Asian	64 (4.48%)	35 (3.78%)		36 (4.34%)	34 (4.10%)	
Other	133 (9.32%)	108 (11.66%)		88 (10.62%)	87 (10.49%)	
<b>Ethnicity</b>						
Hispanic	168 (11.77%)	150 (16.20%)	0.002	116 (13.99%)	118 (14.23%)	0.89
Non-Hispanic	1259 (88.23%)	776 (83.80%)		713 (86.01%)	711 (85.77%)	
<b>Comorbidity</b>						
Obesity	494 (34.62%)	303 (32.72%)	0.34	257 (31.00%)	271 (32.69)	0.46
Diabetes	534 (37.42%)	299 (32.29%)	0.011	282 (34.02%)	274 (33.05%)	0.68
Hypertension	1070 (74.98%)	620 (66.95%)	<0.001	581 (70.08%)	575 (69.36%)	0.75
Stroke	68 (4.77%)	41 (4.43%)	0.70	40 (4.83%)	34 (4.10%)	0.48
COPD	36 (2.52%)	8 (0.86%)	0.004	5 (0.60%)	6 (0.72%)	0.76
Coronary artery disease	181 (12.68%)	98 (10.58%)	0.12	83 (10.01%)	85 (10.25%)	0.87
Congestive heart failure	166 (11.63%)	119 (12.85%)	0.38	96 (11.58%)	100 (12.06%)	0.76
<b>Organ Transplanted</b>						
Heart	137 (9.60%)	96 (10.37%)	0.65	76 (9.17%)	76 (9.17%)	

Kidney	1006 (70.50%)	660 (71.27%)		599 (2.26%)	598 (72.14%)	1.00
Liver	254 (17.80%)	148 (15.98%)		135 (16.28%)	137 (16.53%)	
Other	30 (2.10%)	22 (2.38%)		19 (2.29%)	18 (2.17%)	
<b>Years After Transplant Mean (SD)</b>	9.00 (7.89)	9.11 (7.59)	0.73	8.96 (7.84)	9.29 (7.58)	0.37
<b>Immunosuppression</b>						
Mycophenolate	842 (59.00%)	517 (55.83%)	0.13	466 (56.21%)	467 (56.33%)	0.96
Azathioprine	95 (6.66%)	60 (6.48%)	0.87	62 (7.48%)	50 (6.03%)	0.24
Prednisone	875 (61.32%)	563 (60.80%)	0.80	527 (63.57%)	500 (60.55%)	0.21
Tacrolimus	967 (67.76%)	612 (66.09%)	0.40	564 (68.03%)	547 (65.98%)	0.37
Cyclosporine	110 (7.71%)	56 (6.05%)	0.12	46 (5.55%)	54 (6.51%)	0.41
Belatacept	130 (9.11%)	69 (7.45%)	0.16	69 (8.32%)	63 (7.60%)	0.59
Sirolimus	67 (4.70%)	43 (4.64%)	0.95	33 (3.98%)	38 (4.58%)	0.54
Everolimus	16 (1.12%)	8 (0.86%)	0.54	10 (1.21%)	7 (0.84%)	0.46
<b>Vaccine received</b>						
Ad26.COV2.S	64 (4.48%)	4 (0.43%)		41 (4.95%)	4 (0.48%)	
mRNA-1273	600 (42.05%)	74 (7.99%)		347 (41.86%)	68 (8.20%)	
BNT162b2	763 (53.47%)	73 (7.88%)		441 (53.20%)	63 (7.60%)	
None	0 (0.00%)	775 (83.69%)		0 (0.00%)	694 (83.72%)	
<b>OUTCOMES</b>						
<b>SARS-CoV-2 infection</b>	9 (0.63%)	50 (5.40%)	<0.001	9 (1.09%)	23 (2.77%)	0.012
<b>Death from any cause</b>	9 (0.63%)	33 (3.56%)	<0.001	4 (0.48%)	15 (1.81%)	0.011
<b>Death due to COVID-19</b>	0 (0%)	8 (0.86%)	<0.001	0 (0%)	2 (0.24%)	0.50

**Supplemental Table 2.** Adjusted Hazard/Risk ratio (95% CI) of Covid infection or all-cause mortality using either Cox or modified Poisson model in our primary or sensitivity analysis

	Outcome	Statistical Model	Adjusted Hazard/Risk Ratio (95% CI)	P value
Primary Analysis	SARS-CoV-2 infection	Cox model	0.27 (0.13, 0.58)	<0.001
		Modified Poisson	0.28 (0.13, 0.60)	0.001
	All-cause mortality	Cox Model	0.24 (0.06, 0.95)	0.04
		Modified Poisson	Not converge	
Sensitivity Analysis	SARS-CoV-2 infection	Cox model	0.38 (0.17, 0.82)	0.01
		Modified Poisson	0.40 (0.18, 0.87)	0.02
	All-cause mortality	Cox Model	0.21 (0.05, 0.84)	0.03
		Modified Poisson	0.21 (0.05, 0.86)	0.03

Note: Hazard/Risk ratios are adjusted by age, gender, race, ethnicity, transplant type, years after transplant, Mycophenolate, obesity, diabetes mellitus, hypertension, stroke, COPD, coronary artery disease and congestive heart failure.